Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Tyra BiosciencesTYRA +1.65%28 Debt-to-Equity is 0.02 as of Mar. 2026, which is at its 10-year median of 0.02. GuruFocus rates TYRA with a GF Score™ of 28/100. The stock has 2 warning signs investors should review. Among 967 Biotechnology companies, Tyra Biosciences ranks better than 88.11% on this metric.
A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.
The historical rank and industry rank for Tyra Biosciences's Debt-to-Equity or its related term are showing as below:
TYRA'
s Debt-to-Equity Range Over the Past 10 Years
Min: -0.05 Med: 0.02 Max: 0.03
Current: 0.02
During the past 7 years, the highest Debt-to-Equity Ratio of Tyra Biosciences was 0.03. The lowest was -0.05. And the median was 0.02.
TYRA's Debt-to-Equity is ranked better than 88.11% of 967
companies
in the Biotechnology industry
Industry Median: 0.16
vs TYRA: 0.02
Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.
Tyra Biosciences Debt-to-Equity Related Terms
Tyra Biosciences Debt-to-Equity Historical Data
* Premium members only.
The historical data trend for Tyra Biosciences's Debt-to-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TYRA vs SION, IOVA, SNDX: Debt-to-Equity Comparison
For the Biotechnology subindustry, Tyra Biosciences's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Tyra Biosciences Debt-to-Equity vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Tyra Biosciences's Debt-to-Equity distribution charts can be found below:
* The bar in red indicates where Tyra Biosciences's Debt-to-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Tyra Biosciences (TYRA) has a Debt-to-Equity of 0.02 as of Mar. 2026. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Tyra Biosciences and its competitors. This is near median its historical median of 0.02. According to the industry distribution chart, Tyra Biosciences ranks #115 out of 967 companies in the Biotechnology industry, placing it in the top 11.9%.
Is Tyra Biosciences' Debt-to-Equity too high?
Tyra Biosciences' current Debt-to-Equity of 0.02 is near median its 10-year median of 0.02. The Biotechnology industry median Debt-to-Equity is 0.16. Tyra Biosciences' value of 0.02 is 87.5% below this industry median. Based on the distribution chart, Tyra Biosciences ranks #115 out of 967 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Tyra Biosciences has a GF Score™ of 28/100, reflecting its overall financial health beyond just this single metric.
How does Tyra Biosciences' Debt-to-Equity compare to SION and IOVA?
According to the Biotechnology industry distribution chart, Tyra Biosciences ranks #115 out of 967 companies for Debt-to-Equity. This places Tyra Biosciences in the top 12% of its industry — outperforming the majority of peers. The industry median Debt-to-Equity is 0.16. Tyra Biosciences' value of 0.02 is 87.5% below this benchmark. While the company's 10-year median is 0.02 vs. the industry median of 0.16, Tyra Biosciences has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-Equity for a Biotechnology company?
The median Debt-to-Equity among Biotechnology companies is 0.16, based on 967 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-Equity significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Tyra Biosciences's current Debt-to-Equity of 0.02 is 87.5% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-Equity mean?
A high Debt-to-Equity can signal that a stock is expensive relative to its fundamentals. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Tyra Biosciences and its competitors. For the Biotechnology industry, the median Debt-to-Equity is 0.16 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Tyra Biosciences's current Debt-to-Equity is 0.02, which is near median its own 10-year median of 0.02. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Tyra Biosciences stock overvalued right now?
Tyra Biosciences (TYRA) has a current Debt-to-Equity of 0.02. The current Debt-to-Equity is 0.02, which is near median its 10-year median of 0.02 and 87.5% below the Biotechnology industry median of 0.16. Tyra Biosciences' overall GF Score™ is 28/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-Equity calculated?
Debt-to-Equity is calculated from a company's financial statements. For Tyra Biosciences (TYRA), the current Debt-to-Equity is 0.02 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Tyra Biosciences Inc is a clinical-stage biotechnology company focused on developing next-generation precision medicines for large opportunities in targeted oncology and genetically defined conditions, harnessing the power of Fibroblast Growth Factor Receptor (FGFR) biology. The company's in-house precision medicine platform, SNAP, enables rapid and precise drug design through iterative molecular SNAPshots that help to design and predict which product candidates may demonstrate the highest potency, selectivity, and tolerability in the clinic. The various drug candidates in the company's product pipeline are FGFR3, FGFR4/3, and FGFR1/2/3: three clinical-stage, novel small molecules designed to overcome the toxicity and resistance liabilities of first-generation pan-FGFR inhibitors.
28GF Score
Get the complete analysis for TYRA
Debt-to-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TYRA has been successfully added to your 
